A investigator-funded Phase 1a/1B study assessing WP1066 in adult cancer
Latest Information Update: 25 Aug 2021
At a glance
- Drugs WP 1066 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 25 Aug 2021 New trial record
- 12 Aug 2021 According to Moleculin media release, the company will file a US Investigative New Drug application (IND) in H2, 2021 for the treatment of certain adult cancer(s) with WP1066 and identify an institution to commence this associated investigator-funded Phase 1a/1B study.